Japanese biopharmaceutical company Takeda, in partnership with US-based diagnostics company Prometheus Laboratories, has rolled out the CDPATH programme in the US.

CDPATH is a personalised prognostic test that leverages blood tests that predicts the risk of developing severe complications related to Crohn’s Disease (CD).

In combination with a physician’s clinical assessment, the test results can be used to predict the potential risk of developing severe CD complications in three years.

CDPATH is intended for adult patients, aged 18 years and above, diagnosed with CD within the past 10 years, who did not experience serious complications.

Under the CDPATH programme, CD patients can have blood drawn for the CDPATH test at more than 2,500 participating locations across the US.

The test enables the patients with CD to partner with their physicians to figure out a personalised disease management plan, said Takeda.

Takeda Pharmaceuticals U.S.A gastroenterology business unit head Gamze Yüceland said: “At Takeda, we are driven by the challenge of making a meaningful difference in the lives of patients with inflammatory bowel disease, and working with partners to provide solutions that can help transform their care.

“Offering CDPATH at no cost to eligible patients with CD will help deliver an innovative tool to the community that can help inform and personalise CD management.”

Takeda has developed the CDPATH test in collaboration with biotechnology company MiTest Health (MiTest) and Prometheus.

Under the partnership, MiTest Health defined and established the clinical relevance of the CDPATH model through an objective clinical study.

CDPATH has been validated by Prometheus and was approved by the New York State Department of Health (NYS DoH) as a Laboratory Developed Test (LDT).

Prometheus is a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory and serves as the processing laboratory for the CDPATH programme.

Prometheus Laboratories president Mike Walther said: “Prometheus Laboratories is pleased to partner with Takeda on the CDPATH program as they share our commitment to patients.

“CDPATH is a prognostic tool that we believe can be important when considering an appropriate management approach for an individual patient.”

MiTest co-founder Corey Siegel said: “CDPATH will allow healthcare providers to evaluate the potential variability and complexity of Crohn’s disease for each individual patient, and support a more collaborative approach to managing their patient’s CD.”